HiFiBiO raises $37.5M in series B following 2017’s management shuffle

Cash
In August 2017, the biotech appointed new members to its management, including President and CEO Liang Schweizer and Chief Operating Officer Jeff He. (Pixabay)

HiFiBiO Therapeutics has completed a $37.5 million series B funding round, with plans to advance its antibody pipeline in oncology and autoimmune research after expanding its leadership team last summer.

The financing was led by Sequoia China and LYFE Capital, with support from the biotech’s previous series A investors, VI Ventures and Nest.Bio Ventures. New investors included Legend Star Capital and Proxima Ventures, HiFiBiO said in its announcement. Both of the company’s laboratories, in Cambridge, Massachusetts, and Hangzhou, China, are located within Nest.Bio’s incubator facilities.

In August 2017, the biotech appointed new members to its management, including President and CEO Liang Schweizer, Ph.D., who previously held management roles in cancer research at Sanofi and Bristol-Myers Squibb. HiFiBiO also named Jeff He, a former executive VP at ChemPartner, as chief operating officer.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Two of the original founders remain in senior positions, with Colin Brenan, Ph.D., continuing to serve as chief commercial officer and former CEO Fred Dom taking on the role of chief financial officer.

The company’s drug discovery platform, CelliGO, looks to develop therapeutic antibodies and immune system modulators through single-B-cell screening, phenotyping and analysis.

“We are very excited about HiFiBiO Therapeutics’ long-term growth trajectory,” said James Zhao, founding partner at LYFE Capital, citing the company’s ability to generate a number of antibodies in diverse tumor types.